Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

Skip to main content
Fig. 3 | Immunity & Ageing

Fig. 3

From: Novel nanoadjuvants balance immune activation with modest inflammation: implications for older adult vaccines

Fig. 3

Cytokine or chemokine production by young or aged PBMCs is altered by PMA/ionomycin, LPS, or NP treatment. PBMCs from young (n = 6) or aged (n = 4) adults were incubated with either no adjuvants (media), polyanhydride nanoparticles (NP), Micelles (Mi), LPS, PMA/ionomycin (PMA), or cyclic dinucleotide (CDN) adjuvant for 24 h and analyzed for production of cytokines, chemokines, or growth factors. A main effect of treatment was found for IFN-γ, TNFα, CXCL10, GM-CSF (p < 0.05) and trend for CCL4. In all comparisons with significant treatment effects, post hoc analysis show that PMA was greater than media alone (p < 0.05). LPS induced greater production of IFN-γ, GM-CSF and CXCL10 compared to media alone, and post hoc analyses also showed that NP treatment was greater than media alone for GM-CSF only, with a trend (p = 0.06) for TNFα > media. A main effect of age was observed for all cytokines shown (p < 0.05), with lower concentrations in culture supernatants of cells obtained from older adults. A significant treatment by age interaction for IFN-γ activation was found as indicated by *+ in the IFN-γ group

Back to article page